Tenax Therapeutics (TENX) Change in Account Payables (2024 - 2026)
Tenax Therapeutics recorded quarterly Change in Account Payables of $305000.0 in Q1 2026, down 29.4% quarter-over-quarter from $432000.0 in Q4 2025, and up 123.14% year-over-year from $136684.8 in Q1 2025.
Tenax Therapeutics' Change in Account Payables history runs 3 years deep, the most recent figure standing at $305000.0 for Q1 2026.
- In Q1 2026, Change in Account Payables rose 123.14% year-over-year to $305000.0; the TTM figure through Mar 2026 stood at $4.5 million (up 505.78% YoY), while the FY2025 annual figure was $2.9 million, up 171.56% from the prior year.
- Change in Account Payables came in at $305000.0 for Q1 2026 at Tenax Therapeutics, down from $432000.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $5.0 million in Q3 2025 to a low of -$1.3 million in Q1 2025.
- A 3-year average of $472333.3 and a median of $305000.0 in 2026 frame the typical range for Change in Account Payables.
- On a YoY basis, Change in Account Payables climbed as much as 612.85% in 2025 and fell as far as 477.83% in 2025.
- Tenax Therapeutics' Change in Account Payables stood at $1.6 million in 2024, then slumped by 72.57% to $432000.0 in 2025, then dropped by 29.4% to $305000.0 in 2026.
- According to Business Quant data, Change in Account Payables over the past three periods registered $305000.0, $432000.0, and $5.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -3.26 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 35.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Tenax Therapeutics | 542.72 Mn | 542.72 Mn | - | 305,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 305,000.00 |
| Mar 31, 2026 | 305,000.00 |
| Dec 31, 2025 | 432,000.00 |
| Dec 31, 2025 | 432,000.00 |
| Sep 30, 2025 | 5.05 Mn |
| Sep 30, 2025 | 5.05 Mn |
| Jun 30, 2025 | -1.28 Mn |
| Jun 30, 2025 | -1.28 Mn |
| Mar 31, 2025 | -1.32 Mn |
| Mar 31, 2025 | -1.32 Mn |
| Dec 31, 2024 | 1.58 Mn |
| Dec 31, 2024 | 1.58 Mn |
| Sep 30, 2024 | 708,000.00 |
| Sep 30, 2024 | 708,000.00 |
| Jun 30, 2024 | -221,000.00 |
| Jun 30, 2024 | -221,000.00 |
| Mar 31, 2024 | -1.00 Mn |
| Mar 31, 2024 | -1.00 Mn |